Results 221 to 230 of about 218,532 (303)

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten   +9 more
wiley   +1 more source

Documented End‐of‐Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease and atypical parkinsonism are characterized by motor and non‐motor symptoms. As the disease advances, planning for end‐of‐life (EoL) care becomes increasingly important. However, consensus‐based European guidelines for advance care planning and documentation of EoL care preferences for parkinsonism are lacking ...
Bauke W. Dijkstra   +30 more
wiley   +1 more source

Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia. [PDF]

open access: yesNeurology
Marth L   +50 more
europepmc   +1 more source

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

open access: yesMovement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan   +4 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy